Wednesday, August 24, 2016

Oramed hopes to start Phase 3 oral insulin trial next year

Oramed hopes to start Phase 3 oral insulin trial next year

August 23, 2016 by · Leave a Comment 

Tweet After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss proceeding with a Phase 3 clinical trial in 2017. “We believe that our data set shows that oral insulin works, which […]

In conversation with Ben Haynor

In conversation with Ben Haynor

August 16, 2016 by · Leave a Comment 

Tweet As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies category and was named the top stock picker in U.S. Health Care Equipment and Supplies in StarMine’s 2013 […]

Parvus developing Navacims to treat autoimmune diseases

Parvus developing Navacims to treat autoimmune diseases

August 9, 2016 by · Leave a Comment 

Tweet Closely-held Parvus Therapeutics is developing a broad therapeutic platform, called Navacims, to treat autoimmune diseases through in vivo expansion and activation of disease-specific regulatory T-cells (T-regs), which normally play a key role in maintaining immune system balance and immune tolerance. “We have extensive preclinical proof-of-concept data, with in vivo reversal of disease in mouse […]

Triumvira targeting cancer with customized T cells

Triumvira targeting cancer with customized T cells

July 26, 2016 by · Leave a Comment 

Tweet Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs). “TACs were designed to use the natural activation and inhibitory pathways of T cells and have the potential to outperform identically-directed chimeric antigen receptor (CAR) T cells,” president and CEO, […]

In conversation with Dr. Paul Lem

In conversation with Dr. Paul Lem

July 19, 2016 by · Leave a Comment 

Tweet As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides fast and inexpensive sample-to-result DNA testing. One-in-three people carry genetic mutations and carrying a CYP2C19 mutation can impair drug metabolism. Some […]

Braeburn taking path as pill-free pharma company

Braeburn taking path as pill-free pharma company

July 12, 2016 by · Leave a Comment 

Tweet Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting implants and injectables that improve public health and social cost outcomes associated with drug diversion, misuse and non-compliance. “This is the way of the future,” Behshad […]

Merus Labs moving up the value chain

Merus Labs moving up the value chain

July 5, 2016 by · Leave a Comment 

Tweet After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing existing products and continuing to acquire legacy products that are no longer strategic for major pharmaceutical companies. “Since the fall of 2014, we’ve strengthened the management team […]

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

June 28, 2016 by · Leave a Comment 

Tweet Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella, president and CEO, says in an interview […]

Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

June 21, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage than is typically associated with the use […]

S1 Biopharma to start Phase 2b study in female HSDD by yearend

S1 Biopharma to start Phase 2b study in female HSDD by yearend

June 14, 2016 by · Leave a Comment 

Tweet Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with a second therapy, Orexa, for male HSDD. “HSDD is characterized by a lack or absence of sexual fantasies and […]

Next Page »

Email Newsletters with Constant Contact
Google+